Accéder au contenu
Merck

03-0146-00

SMC® Amyloid Beta 42 High Sensitivity Immunoassay Kit

Used for ultrasensitive quantification of Amyloid Beta 1-42 (Aβ42) in human, rat or mouse plasma or cerebrospinal fluid (CSF)

Synonyme(s) :

Abeta 1-42 immunoassay kit, Abeta 42 Single Molecule Counting Kit, Abeta 42 immunoassay kit, Abeta 42 ultra-sensitive Immunoassay

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

NACRES:
NA.84
UNSPSC Code:
12161503
Species reactivity:
human
Technique(s):
single molecule counting: suitable
Usage:
 kit sufficient for 96 wells
Compatibility:
for use with for use with FemtoQuest and SMCxPRO® instruments (validated)
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


Nom du produit

SMC® Amyloid Beta 42 High Sensitivity Immunoassay Kit,

Quality Level

description

Used for ultrasensitive quantification of Amyloid Beta 1-42 (Aβ42) in human, rat or mouse plasma or cerebrospinal fluid (CSF)

product line

SMC®

usage

 kit sufficient for 96 wells

species reactivity

human

technique(s)

single molecule counting: suitable

input

serum
plasma
cerebrospinal fluid (CSF)

compatibility

for use with for use with FemtoQuest and SMCxPRO® instruments (validated)

shipped in

wet ice

storage temp.

2-8°C

General description

Amyloid Beta 1-42 (Aβ1-42) is a peptide derived from the proteolytic cleavage of the amyloid precursor protein (APP), a transmembrane protein implicated in neuronal development and function. Aβ1-42 is particularly notable for its propensity to aggregate into toxic oligomers and fibrils, which are key components of amyloid plaques found in the brains of individuals with neurodegenerative diseases, especially Alzheimer′s disease (AD).

Aβ1-42 plays a critical role in the pathogenesis of Alzheimer′s disease. Elevated levels of Aβ1-42 are associated with the development of amyloid plaques, which can disrupt neuronal function, trigger neuroinflammation, and lead to neuronal cell death. The presence of Aβ1-42 in the cerebrospinal fluid (CSF) is often inversely correlated with cognitive decline, making it a valuable biomarker for early diagnosis and monitoring of Alzheimer′s disease. Understanding the function and implications of Aβ1-42 is essential for developing targeted therapies aimed at reducing amyloid burden and mitigating its detrimental effects on brain health in neurodegenerative conditions.

Application

Neuroscience/Neurological Disorders/Signaling

Features and Benefits

  • High Sensitivity Detection: Precisely quantifies Amyloid Beta 1-42 at femtogram/mL levels in plasma or CSF.
  • Improved Dynamic Range: Enhanced signal-to-noise ratio with reduced background interference for reliable assay performance.
  • User-Friendly Workflow: Utilizes a familiar sandwich immunoassay format while ensuring high sensitivity for Aβ1-42 detection.
  • Automation-Ready: Compatible with automated liquid handling systems, reducing manual steps and increasing lab efficiency.

Packaging

96 well assay

Analysis Note

  • Sensitivity: LLOQ 980 fg/mL* (SMCxPRO® Instrument)
  • Standard Curve Range: 244-250,000 fg/mL
  • Intra-assay CV: <15%
  • Inter-assay CV: <20%
  • Linearity: CSF: 100%
  • Recovery: Plasma: 94% CSF: 92%

*Indicative LLOQ created from average of 14 independent in house runs, where >80% met same value defined with CV & Recovery +/- 20%. Refer to CoA for lot specific performance.

Other Notes

Although Amyloid Beta 42 was detectable in mouse and rat samples, the assay has not been verified for these species.

Legal Information

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany
SMC is a registered trademark of Singulex
SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

target_organs

Respiratory Tract

Classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - ED ENV 1 - Eye Irrit. 2 - Repr. 1B - STOT RE 2 Inhalation



Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents



Chia-Liang Tsai et al.
Journal of clinical medicine, 8(10) (2019-10-09)
Nondemented people with a family history of Alzheimer's disease (ADFH) and the ApoE-4 allele have been demonstrated to show a trend for a higher probability of cognitive decline and aberrant levels of cognitive-related biomarkers. However, the potential interactive effects on



Numéro d'article de commerce international

RéférenceGTIN
03-0146-0004054839166433